Skip to main content

Advertisement

Log in

Effect of mycophenolate sodium in scleroderma-related interstitial lung disease

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study aims to determine the effectiveness of mycophenolate sodium (MS) in patients with scleroderma (SSc)-related interstitial lung disease (ILD). In a prospective observational study, we evaluated 14 consecutive SSc-ILD patients who were treated with MS for 12 months. The effect of MS on lung function was examined by using longitudinal data analytic methods. Wilcoxon rank–sum tests were used to examine the forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) by pulmonary function testing. As a group, the median values for FVC, FEV1 and DLCO did not change significantly after 12 months of MS therapy and fulfilled the definition of stable disease by the American Thoracic Society. Individually, after 12 months of treatment, 6 out of 14 patients showed a pulmonary improvement defined as an increase of more than 10% in FVC, and 5 out of 14 patients remained stable. By contrast, the median FVC had declined a non-significant 7.2% from the previous 12 months before MS initiation. No significant drug adverse effects were registered. These prospective data suggest that MS is a safe and well-tolerated therapy for SSc-ILD patients, and it is capable of preventing functional pulmonary deterioration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin N Am 29:371–390

    Article  Google Scholar 

  2. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P (2001) Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 28:2454–2459

    PubMed  CAS  Google Scholar 

  3. Steen V, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444

    Article  PubMed  CAS  Google Scholar 

  4. Altman R, Medsger TA Jr, Bloch D, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413

    Article  PubMed  CAS  Google Scholar 

  5. Hubbard R, Venn A (2002) The impact of coexisting connective tissue disease on survival on patients with fibrosing alveolitis. Rheumatology (Oxford) 41:676–679

    Article  CAS  Google Scholar 

  6. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M et al (1992) Mortality in systemic sclerosis (scleroderma). Q J Med 298:139–148

    Google Scholar 

  7. Silver RM, Warrick JH, Kinsella M, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844

    PubMed  CAS  Google Scholar 

  8. White B, Moore WC, Wigley FM, Hui Qing Xiao, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947–954

    PubMed  CAS  Google Scholar 

  9. Tashkin DP, Elashoff R, Clements PJ, Scleroderma Lung Study (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666

    Article  PubMed  CAS  Google Scholar 

  10. Hoyles R, Ellis R, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomised, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970

    Article  PubMed  CAS  Google Scholar 

  11. Davas EM, Pepas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455–461

    Article  PubMed  CAS  Google Scholar 

  12. Varai G, Earle L, Jiménez SA, Steinert RM, Varga J (1998) A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 25:1325–1329

    PubMed  CAS  Google Scholar 

  13. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29:298–304

    PubMed  CAS  Google Scholar 

  14. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conferti ML et al (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29:731–736

    PubMed  CAS  Google Scholar 

  15. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29:2371–2378

    PubMed  CAS  Google Scholar 

  16. Mittal G, Udwadia Z, Joshi VR (2003) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 30:1121–1122

    PubMed  Google Scholar 

  17. Airò P, Danieli E, Parrinello G, Frassi, Cavazzana I, Scarsi M et al (2004) Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 22:573–578

    PubMed  Google Scholar 

  18. Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M et al (2005) Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 64:1343–1346

    Article  PubMed  CAS  Google Scholar 

  19. Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN et al (2007) Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27:357–361

    Article  PubMed  CAS  Google Scholar 

  20. Simeón CP, Fonollosa V, Tolosa C, Selva A, Solans R, Palliza E et al (2008) Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis related interstitial lung disease: a long term study. Open Respir Med J 2:39–45

    Article  Google Scholar 

  21. Tahskhin D, Elashoff R, Clements P, SLR group (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026–1034

    Article  Google Scholar 

  22. Liossis SN, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45:1005–1008

    Article  CAS  Google Scholar 

  23. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK et al (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130:30–36

    Article  PubMed  CAS  Google Scholar 

  24. Zamora AC, Wolters PJ, Collard HR, Connolly K, Elicker B, Webb W et al (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102:150–155

    Article  PubMed  Google Scholar 

  25. Gerbino A, Goss C, Molitor J (2008) Effect of mycohenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133:455–460

    Article  PubMed  CAS  Google Scholar 

  26. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas L (2010) Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 10:1167–1168

    Article  Google Scholar 

  27. Vanthuyne M, Bockmans D, Westhovens R, Roufosse F, Cogan E, Coche E et al (2007) A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 25:287–292

    PubMed  CAS  Google Scholar 

  28. Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanism of action. Immunopharmacology 47:85–118

    Article  PubMed  CAS  Google Scholar 

  29. Appel GB, Radhakrishnan J, Ginzler EM (2005) Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 80(2 Suppl):S265–S271

    Article  PubMed  CAS  Google Scholar 

  30. Shimizu H, Takahashi M, Takeda S, Inoue S, Fujishiro J, Hakamata Y et al (2004) Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 77:1661–1667

    Article  PubMed  CAS  Google Scholar 

  31. Guo H, Leung JC, Chan LY et al (2005) Modulation of intrapulmonary TGF-ß expression by mycophenolate mofetil in lupus prone MRL/pr mice. Lupus 14:583–592

    Article  PubMed  CAS  Google Scholar 

  32. Budde K, Curtis J, Knoll G (2004) Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplantation 4:237–243

    Article  CAS  Google Scholar 

  33. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum 23:581–590

    Article  Google Scholar 

  34. LeRoy EC, Black C, Fleishmayer R, Jablonska S, Krieg T, Medsger TA et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–208

    PubMed  CAS  Google Scholar 

  35. Simeón CP, Armadans L, Fonollosa V, Vilardell M, Candell J, Tolosa C et al (1997) Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 56:723–728

    Article  PubMed  Google Scholar 

  36. Roca J, Sanchis J, Agustí-Vidal A, Segarra F, Navajas D, Rodríguez-Roisin R et al (1986) Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir 22:217–224

    PubMed  CAS  Google Scholar 

  37. American Thoracic Society (ATS) (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646–664

    Google Scholar 

  38. Antoniou KM, Wells AU (2008) Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 20:686–691

    Article  PubMed  CAS  Google Scholar 

  39. Behr J, Furst DE (2008) Pulmonary function tests. Rheumatology (Oxford) 47(Suppl 5):v65–v67

    Article  Google Scholar 

  40. Nihtyanova SI, Brogh GM, Black CM, Denton CP (2007) Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford) 46:442–445

    Article  CAS  Google Scholar 

  41. Derk, Grace E, Shenin M, Naik M, Schultz S, Xiong W et al (2009) Rheumatology 48:1595–1599

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carmen Pilar Simeón-Aznar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simeón-Aznar, C.P., Fonollosa-Plá, V., Tolosa-Vilella, C. et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 30, 1393–1398 (2011). https://doi.org/10.1007/s10067-011-1823-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-011-1823-1

Keywords

Navigation